Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242


Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.

Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA.

Mol Cancer. 2014 Apr 28;13:93. doi: 10.1186/1476-4598-13-93.


LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization.

Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA.

Genes Chromosomes Cancer. 2009 Aug;48(8):679-93. doi: 10.1002/gcc.20675.


Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma.

Yen CC, Chen WM, Chen TH, Chen WY, Chen PC, Chiou HJ, Hung GY, Wu HT, Wei CJ, Shiau CY, Wu YC, Chao TC, Tzeng CH, Chen PM, Lin CH, Chen YJ, Fletcher JA.

Int J Oncol. 2009 Oct;35(4):775-88.


Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma.

Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, Novokmet A, Malkin D.

Cancer Res. 2010 Jan 1;70(1):160-71. doi: 10.1158/0008-5472.CAN-09-1902.


Doxorubicin Inhibits Proliferation of Osteosarcoma Cells Through Upregulation of the Notch Signaling Pathway.

Ji P, Yu L, Guo WC, Mei HJ, Wang XJ, Chen H, Fang S, Yang J.

Oncol Res. 2014;22(4):185-91. doi: 10.3727/096504015X14343704124340.


Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness.

Zhang P, Yang Y, Nolo R, Zweidler-McKay PA, Hughes DP.

Oncogene. 2010 May 20;29(20):2916-26. doi: 10.1038/onc.2010.62. Epub 2010 Mar 8. Erratum in: Oncogene. 2012 Nov 1;31(44):4732.


DEC2 expression is positively correlated with HIF-1 activation and the invasiveness of human osteosarcomas.

Hu T, He N, Yang Y, Yin C, Sang N, Yang Q.

J Exp Clin Cancer Res. 2015 Feb 28;34:22. doi: 10.1186/s13046-015-0135-8.


Overexpression of the LSAMP and TUSC7 genes in acute myeloid leukemia following microdeletion/duplication of chromosome 3.

Coccaro N, Zagaria A, Tota G, Anelli L, Orsini P, Casieri P, Cellamare A, Minervini A, Impera L, Minervini CF, Brunetti C, Mestice A, Carluccio P, Cumbo C, Specchia G, Albano F.

Cancer Genet. 2015 Oct;208(10):517-22. doi: 10.1016/j.cancergen.2015.07.006. Epub 2015 Aug 4.


HES1, a target of Notch signaling, is elevated in canine osteosarcoma, but reduced in the most aggressive tumors.

Dailey DD, Anfinsen KP, Pfaff LE, Ehrhart EJ, Charles JB, Bønsdorff TB, Thamm DH, Powers BE, Jonasdottir TJ, Duval DL.

BMC Vet Res. 2013 Jul 1;9:130. doi: 10.1186/1746-6148-9-130.


Diallyl trisulfide inhibits proliferation, invasion and angiogenesis of osteosarcoma cells by switching on suppressor microRNAs and inactivating of Notch-1 signaling.

Li Y, Zhang J, Zhang L, Si M, Yin H, Li J.

Carcinogenesis. 2013 Jul;34(7):1601-10. doi: 10.1093/carcin/bgt065. Epub 2013 Feb 20.


Long noncoding RNA BCAR4 promotes osteosarcoma progression through activating GLI2-dependent gene transcription.

Chen F, Mo J, Zhang L.

Tumour Biol. 2016 Oct;37(10):13403-13412. Epub 2016 Jul 27.


Frequent reduction or loss of DCC gene expression in human osteosarcoma.

Horstmann MA, Pösl M, Scholz RB, Anderegg B, Simon P, Baumgaertl K, Delling G, Kabisch H.

Br J Cancer. 1997;75(9):1309-17.


Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma.

Li W, He X, Xue R, Zhang Y, Zhang X, Lu J, Zhang Z, Xue L.

Pathol Res Pract. 2016 Oct;212(10):861-866. doi: 10.1016/j.prp.2016.06.013. Epub 2016 Jun 27.


MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.

Chen Y, Huang T, Yang X, Liu C, Li P, Wang Z, Zhi S.

Oncol Rep. 2018 Oct;40(4):2251-2259. doi: 10.3892/or.2018.6601. Epub 2018 Jul 26.


Expression and significance of Kruppel-like factor 6 gene in osteosarcoma.

Chen K, Chen Y, Zhu XD, Bai YS, Wei XZ, Wang CF, Chen ZQ, Li M.

Int Orthop. 2012 Oct;36(10):2107-11. doi: 10.1007/s00264-012-1626-2. Epub 2012 Aug 2.


Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion.

Nagao-Kitamoto H, Setoguchi T, Kitamoto S, Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M, Kitajima S, Yoshioka T, Maeda S, Yonezawa S, Komiya S.

Cancer Lett. 2015 Jan 28;356(2 Pt B):855-61. doi: 10.1016/j.canlet.2014.10.042. Epub 2014 Nov 11.


MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2.

Jiang B, Mu W, Wang J, Lu J, Jiang S, Li L, Xu H, Tian H.

J Exp Clin Cancer Res. 2016 Apr 19;35:69. doi: 10.1186/s13046-016-0348-5.


Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.

Knowles HJ, Schaefer KL, Dirksen U, Athanasou NA.

BMC Cancer. 2010 Jul 16;10:372. doi: 10.1186/1471-2407-10-372.


Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior.

Jianwei Z, Enzhong B, Fan L, Jian L, Ning A.

Tumour Biol. 2013 Apr;34(2):1097-105. doi: 10.1007/s13277-013-0651-0. Epub 2013 Jan 16.


Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

Patiño-García A, Zalacain M, Folio C, Zandueta C, Sierrasesúmaga L, San Julián M, Toledo G, De Las Rivas J, Lecanda F.

Clin Cancer Res. 2009 Aug 15;15(16):5082-91. doi: 10.1158/1078-0432.CCR-09-0300. Epub 2009 Aug 11.

Supplemental Content

Support Center